-
Mashup Score: 0Clotting and bleeding in Behçet's syndrome - 3 day(s) ago
A 62-year-old woman with long-standing Behçet’s syndrome was treated with infliximab and varying doses of prednisolone. She had had a provoked pulmonary embolism 8 years before, following an admission with norovirus. She also had a stable low-level IgA lambda paraproteinemia, without features of multiple myeloma or immunoparesis.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Once-monthly garadacimab for more than 2 years in patients with hereditary angioedema was well tolerated and efficacious in reducing monthly attack rate and improving HRQoL. These results reveal the potential of long-term prophylactic treatment with 200 mg once-monthly garadacimab towards complete disease control of patients with hereditary angioedema.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
Hydroxyurea dose escalation to MTD with dose optimisation significantly improved clinical responses and treatment outcomes, without increasing toxicities in children with sickle cell anaemia in sub-Saharan Africa.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa - 5 day(s) ago
Realizing Effectiveness Across Continents with Hydroxyurea (REACH) is a large prospective open-label, non-randomised trial of hydroxyurea (hydroxycarbamide) for children aged 1–10 years with sickle cell anaemia in sub-Saharan Africa. The trial is currently ongoing and enrolled 635 children between July 4, 2014, and Nov 11, 2016. 606 children were given hydroxyurea and 522 children remained in the trial receiving treatment for a median of 93 months (IQR 84–97). Hydroxyurea was started at a fixed dose of 15–20 mg/kg per day for 6 months, followed by dose escalation to maximum tolerated dose (MTD), defined in the study as mild bone marrow suppression (typically, an absolute neutrophil count [ANC] of 2·0–4·0 × 109 cells per L).
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Celebrating our community: a call for essays and art - 7 day(s) ago
October, 2024, will see the 10-year anniversary of The Lancet Haematology, which was first published in 2014. To mark this occasion, we are publishing a special issue, and we would like to invite you to get involved. We are calling for essays and art pieces on the theme celebrating our community to be published in the In Focus section of the Journal. We chose to celebrate the community you have helped us create around the Journal in these past 10 years, supporting our commitment to publishing content that advocates change in, or illuminates, haematological clinical practice.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Universal health coverage for children with cancer - 11 day(s) ago
A huge global inequality related to cancer is the difference in overall survival of children with cancer in low-income and middle-income countries (LMICs; survival rates of 80%). The 2018 WHO Global Initiative for Childhood Cancer has an overall goal to achieve at least 60% survival rates for all children with cancer by 2030, which will be achieved by implementing four pillars set out in the CureAll Framework: 1) centres of excellence and care networks to increase access to quality health services; 2) universal health coverage (UHC) and integration of childhood cancer; 3) regimens optimised for delivery of quality diagnostic and treatment services; and 4) evaluation and monitoring with information systems to improve outcomes.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 55
Explore the current issue of The Lancet Haematology, a monthly journal dedicated to publishing content that advocates change in, or illuminates, haematological clinical practice
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 56
Combination of sintilimab with P-GEMOX seems to be an active and safe first-line regimen for patients with advanced ENKTL.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? - 16 day(s) ago
In the past 15 years, treatment frameworks for newly diagnosed multiple myeloma have radically changed. It is important to recall that as recently as 2010, Rajkumar and colleagues1 presented ECOG E4A03, which was a phase 3 trial examining the role of lenalidomide, combined with two different dosing regimens for dexamethasone, that showed a 68% overall response rate (ORR; 10% complete remission rate) after four cycles of therapy, a result considered to be astounding at the time. Fast forward to 2024, the use of triplet induction has nearly been supplanted by four component regimens, typically including an immunomodulatory drug, a proteasome inhibitor, a steroid, and the newest addition, an anti-CD38 antibody.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14
Although the study did not achieve the prespecified complete response threshold, Isa-KRd induced deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma. The treatment proved safe and consistent with similar regimens in this setting.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
Thanks for taking part! The correct answer is dysfibrinogenaemia. Read the full clinical picture here: https://t.co/DHezS0Uprv